CY1124325T1 - Νεα μεθοδος για παρασκευη υδατο-διαλυτης φορσκολινης - Google Patents

Νεα μεθοδος για παρασκευη υδατο-διαλυτης φορσκολινης

Info

Publication number
CY1124325T1
CY1124325T1 CY20211100478T CY211100478T CY1124325T1 CY 1124325 T1 CY1124325 T1 CY 1124325T1 CY 20211100478 T CY20211100478 T CY 20211100478T CY 211100478 T CY211100478 T CY 211100478T CY 1124325 T1 CY1124325 T1 CY 1124325T1
Authority
CY
Cyprus
Prior art keywords
preparation
new method
forscolin
solvent
water
Prior art date
Application number
CY20211100478T
Other languages
English (en)
Inventor
Andreas Kubin
Original Assignee
SciPharm S.à r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SciPharm S.à r.l. filed Critical SciPharm S.à r.l.
Publication of CY1124325T1 publication Critical patent/CY1124325T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε μία νέα μέθοδο για παρασκευή συμπλόκου φορσκολίνης και κυκλοδεξτρίνης και συμπλοκών εγκλεισμού φορσκολίνης και γ-κυκλοδεξτρινών που έχουν αναλογία βάρους 1:0,2 έως 1:4 (β/β). Επίσης παρέχονται φαρμακευτικές συνθέσεις που περιλαμβάνουν το εν λόγω σύμπλοκο και χρήση αυτών.
CY20211100478T 2017-01-09 2021-06-01 Νεα μεθοδος για παρασκευη υδατο-διαλυτης φορσκολινης CY1124325T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17150644 2017-01-09
PCT/EP2018/050447 WO2018127600A1 (en) 2017-01-09 2018-01-09 Novel process for preparing water soluble forskolin

Publications (1)

Publication Number Publication Date
CY1124325T1 true CY1124325T1 (el) 2022-07-22

Family

ID=57868023

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100478T CY1124325T1 (el) 2017-01-09 2021-06-01 Νεα μεθοδος για παρασκευη υδατο-διαλυτης φορσκολινης

Country Status (17)

Country Link
US (1) US11234957B2 (el)
EP (1) EP3565602B1 (el)
JP (1) JP7138643B2 (el)
KR (1) KR102583356B1 (el)
CN (1) CN110325217B (el)
CY (1) CY1124325T1 (el)
DK (1) DK3565602T3 (el)
ES (1) ES2872223T3 (el)
HR (1) HRP20210863T1 (el)
HU (1) HUE054617T2 (el)
LT (1) LT3565602T (el)
PL (1) PL3565602T3 (el)
PT (1) PT3565602T (el)
RS (1) RS61915B1 (el)
SG (1) SG11201906321WA (el)
SI (1) SI3565602T1 (el)
WO (1) WO2018127600A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065181T2 (hu) 2020-01-23 2024-05-28 Scipharm S A R L 7-deacetilforskolin és PVP komplexe

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
JP3040015B2 (ja) 1991-08-21 2000-05-08 日研化学株式会社 フォルスコリンの包接化合物
IT1294205B1 (it) 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
GB2419095B (en) * 2003-05-20 2008-03-26 Hayashibara Biochem Lab Water-soluble isoflavone composition, its preparation and use
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
JP2008508332A (ja) * 2004-08-02 2008-03-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ピロキシカム：ベータシクロデキストリン包接化合物の製造方法
BRPI0705319A2 (pt) * 2007-07-23 2009-07-21 Uniao Brasileira De Educacao Manedora Da Pucrs processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica
EP2253627A1 (en) 2009-05-21 2010-11-24 ERREGIERRE S.p.A. Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.
CN103768616B (zh) * 2014-01-08 2015-08-05 中国科学院昆明植物研究所 毛萼乙素环糊精包合物、含有该包合物的药物组合物、其制备方法及应用

Also Published As

Publication number Publication date
PL3565602T3 (pl) 2021-09-13
EP3565602A1 (en) 2019-11-13
CN110325217A (zh) 2019-10-11
SG11201906321WA (en) 2019-08-27
ES2872223T3 (es) 2021-11-02
KR102583356B1 (ko) 2023-09-26
JP2020505339A (ja) 2020-02-20
US11234957B2 (en) 2022-02-01
PT3565602T (pt) 2021-05-26
HRP20210863T1 (hr) 2021-08-20
EP3565602B1 (en) 2021-03-03
CN110325217B (zh) 2023-08-08
SI3565602T1 (sl) 2021-07-30
RS61915B1 (sr) 2021-06-30
LT3565602T (lt) 2021-06-25
US20210145791A1 (en) 2021-05-20
KR20190107690A (ko) 2019-09-20
HUE054617T2 (hu) 2021-09-28
DK3565602T3 (da) 2021-06-07
JP7138643B2 (ja) 2022-09-16
WO2018127600A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CY1121949T1 (el) Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
BR112016016580A2 (pt) Polissacarídeos capsulares de streptococcus pneumoniae e conjugados dos mesmos
BR112017013661A2 (pt) conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
CY1121480T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν δοτες νιτροξυλιου
CO2018013497A2 (es) Conjugados de anticuerpo y fármaco anti-egfr
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
CY1123194T1 (el) Νεες αντιβακτηριακες ενωσεις
CY1120628T1 (el) Συνθεση με βαση τα φλαβονοειδη για φαρμακευτικη, διατροφικη ή καλλυντικη χρηση που εχουν ενισχυμενη αντιοξειδωτικη δραση
WO2019118411A3 (en) Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
CY1123574T1 (el) Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CY1122725T1 (el) Αποσμητικη συνθεση που περιλαμβανει ενα μειγμα αλφα, βητα και γαμμα κυκλοδεξτρινων
CY1124325T1 (el) Νεα μεθοδος για παρασκευη υδατο-διαλυτης φορσκολινης
CL2016003155A1 (es) Composiciones de cuidado bucal
CO2020003134A2 (es) Moduladores de la expresión de enac
ZA201908446B (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
CY1125762T1 (el) Νεα απο του στοματος σκευασματα βελινοστατης
CY1124177T1 (el) Ενωσεις χρησιμες για την αναστολη του ror-γαμμα-τ
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола